Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice

Gut

Volumn 55, Issue 2, 2006, Pages 182-190

  Verdu E F ^a,b   Bercik, P ^b   Verma Gandhu, M ^b   Huang, X X ^b   Blennerhassett, P ^b   Jackson, W ^b   Mao, Y ^b   Wang, L ^b   Rochat, F ^c   Collins, S M ^b  

^a Division of Gastroenterology   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DEXAMETHASONE; HISTAMINE; MYELOPEROXIDASE; NEBACETIN; NEUROTRANSMITTER; PROBIOTIC AGENT; SODIUM CHLORIDE; SUBSTANCE P;

ABDOMINAL DISTENSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC INDUCED VISCERAL HYPERSENSITIVITY; ANTIBODY LABELING; ARTICLE; BACTERIUM CULTURE; CELL FUNCTION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT FUNCTION; HISTOPATHOLOGY; HYPERSENSITIVITY; IMMUNOREACTIVITY; INFLAMMATORY CELL; INTESTINE FLORA; LACTOBACILLUS PARACASEI; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE CELL;

ABDOMINAL PAIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CULTURE MEDIA, CONDITIONED; DEXAMETHASONE; ELECTROMYOGRAPHY; FEMALE; HYPERALGESIA; INTESTINES; IRRITABLE BOWEL SYNDROME; MICE; MICE, INBRED BALB C; PEROXIDASE; PHYSICAL STIMULATION; PROBIOTICS; SUBSTANCE P;

EID: 30944444119     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.066100     Document Type: Article

References (41)

1. Agreus L, Svardsudd K, Talley NJ, et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 2001;96:2905-11.
2. Locke GR III. Natural history of irritable bowel syndrome and durability of the diagnosis. Rev Gastroenterol Disord 2003;S12:12-17.
3. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-19.
4. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003;124:1662-71.
5. Alun-Jones V, Wilson AJ, Hunter JO, et al. The aetiological role of antibiotic prophylaxis with hysterectomy in irritable bowel syndrome. J Obstet Gynaecol 1984;5:S22-3.
6. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhea. Lancet 1996;347:150-3.
7. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999;318:505-6.
8. Collins SM, Piche T, Rampal P. The putative role of inflammation in irritable bowel syndrome. Gut 2001;49:743-5.
9. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83.
10. Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial. Gut 2004;53:1459-64.
11. Cebra JJ, Periwal SB, Lee G, et al. Development and maintenance of the gut-associated lymphoid tissue (GALT): the roles of enteric bacteria and viruses. Dev Immunol 1998;6:13-18.
12. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004;4:478-85.
13. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-9.
14. Madden JA, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002;88:S67-72.
15. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
16. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6.
17. Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology 1997;113:1224-32.
18. Barbara G, De Giorgio R, Deng Y, et al. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 2001;120:1729-36.
19. Bercik P, Wang L, Verdú EF, et al. Visceral hyperalgesia and intestinal dysmotlity in a mouse model of post infective gut dysfunction. Gastroenterology 2004;127:179-87.
20. Van Der Waaij D, Sturm CA. Antibiotic decontamination of the digestive tract of mice. Technical procedures. Lab Anim Care 1968;18:1-10.
21. Van Der Waaij D, Berghuis-De Vries JM, Korthals Altes C, et al. Oral dose and faecal concentrations of antibiotics during antibiotic decontamination in mice and in a patient. J Hyg Camb 1974;73:197-203.
22. Verdu EF, Bercik P, Bergonzelli G, et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of post-infective gut dysfunction. Gastroenterology 2004;127:826-37.
23. Guigoz Y, Rachat F, Perruisseau-Carrier G, et al. Effects of oligosaccharide on the faecal flora and non-specific immune system in elderly people. Nutr Res, 22:13-25.
24. Kamm K, Hoppes S, Breves G, et al. Effect of the probiotic yeast Saccaromyces boulardii on the neurochemistry of myenteric neurons in pig jejunum. Neurogastroenterol Motil 2004;16:53-60.
25. Schneider J, Jehle EC, Starlinger MJ, et al. Neurotransmitter coding of enteric neurons in the submucous plexus is changed in non-inflamed rectum of patients with Crohn's disease. Neurogastroenterol Motil 2001;13:255-64.
26. Verdu EF, Deng Y, Bercik P, et al. Modulatory effects of estrogen in two murine models of experimental colitis. Am J Physiol Gastrointest Liver Physiol 2002;283:G27-36.
27. Barren RP, Benoliel R, Zeltser R, et al. Effect of dexamemasone and dypirone on lingual and inferior alveolar nerve hypersensitivity following third molar extractions: preliminary report. J Orofac Pain 2004;18:62-8.
28. Hong D, Byers MR, Oswald RJ. Dexamethasone treatment reduces sensory neuropeptides and nerve sprouting reactions in injured teeth. Pain 1993;55:171-81.
29. Piedimonte G, McDonald DM, Nadel JA. Endopeptidase and kinase II mediate glucocorticoid inhibition of neurogenic inflammation in the rat trachea. J Clin Invest 1991;88:40-4.
30. Verma-Gandhu M, Bercik P, Blennerhassett P, et al. Immunodeficiency and visceral hyperalgesia: A putative mechanisms for abdominal pain in AIDS patients. Gastroenterology 2004;126:A161.
31. Dobins III WO, Herrero BA, Mansbach CM. Morphologic alterations associated with neomycin induced malabsorption. Am J Med Sci 1968;255:63-77.
32. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.
33. Hurst SM, Stanisz AM, Sharkey KA, et al. Interleukin 1 beta-induced increase in substance P in rat myenteric plexus. Gastroenterology 1993;105:1754-60.
34. Miampamba M, Sharkey KA. Distribution of calcitonin gene-related peptide, somatostatin, substance P and vasoactive intestinal polypepride in experimental colitis in rats. Neurogastroenterol Motil 1998;10:315-29.
35. Gonkowski S, Kaminska B, Bossowska A, et al. The influence of experimental Bacteroides fragilis infection on substance P and somatostarin-immunoreactive neural elements in the porcine ascending colon - a preliminary report. Folia Morphol (Warsz) 2003;62:455-57.
36. Piedimonte G, Rodriguez, MM, King KA, et al. Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am J Physiol 1999;277:L831-40.
37. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001;291:881-4.
38. Kamm K, Hoppe S, Breves G, et al. Effects of the probiotic yeast Saccharomyces boulardii on the neurochemistry of myenteric neurones in pig jejunum. Neurogastroenterol Motil 2004;16:53-60.
39. Tobiassen RO, Sorhaug T, Stepaniak L. Characterization of an intracellular oligopeptidase from Ladobacillus paracasei. Appl Environ Microbiol 1997;63:1284-7.
40. Huerta C, Garcia Rodriguez LA, Wallander MA, et al. Users of oral steroids are at a reduced risk of developing irritable bowel syndrome. Pharmacoepidemiol Drug Saf 2003;12:583-8.
41. Maxwell PR, Rink E, Kumar D, et al. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002;97:104-8.